Commercial health insurers are tightening coverage parameters for GLP-1 receptor agonists due to escalating prescription volumes and high recurring costs. Payers are requiring documented participation in lifestyle modification programs and specific body-mass index thresholds before approving reimbursement.
Cost Management Strategies
Self-insured employer groups report that metabolic treatments now represent up to 15% of total pharmaceutical expenditure. In response, benefit managers are negotiating value-based contracts tied to long-term health outcomes and patient compliance metrics.